Silence Therapeutics plc's positive results achieved from phase 1 SANRECO study using divesiran for the treatment of patients with polycythemia vera. The global polycythemia vera treatment market size ...
In 2022, the combined research and development (R&D) expenditure of the U.S. pharmaceutical industry consisted of more than $100 billion. While this is a significantly expansive market, approximately ...
Winrevair yielded significant and meaningful clinical benefits for patients with combined post- and precapillary pulmonary ...
Alixorexton’s Phase II performance sets it up for late-stage success, according to analysts at Truist Securities. Alkermes ...
SAN DIEGO--(BUSINESS WIRE)--Iambic Therapeutics, a clinical-stage biotechnology company developing novel therapeutics using its unique AI-driven discovery platform, today announced Enchant™, a ...
For long-term investors, there are plenty of reasons to buy and hold Eli Lilly for not only years but decades.
Getting from point A to B may sound simple, but not so in the formation of fat cells. In a finding with potential drug-development implications, Mitchell A. Lazar, M.D., Ph.D., director of the ...
Denmark's Zealand Pharma said on Thursday it has paused the development of an early-stage obesity drug candidate as it shifts focus to more promising programs. The drug dapiglutide, a GLP-1/GLP-2 ...
June 17 (Reuters) - Aerovate Therapeutics (AVTE.O), opens new tab said on Monday it was scrapping the late-stage development of its lead experimental drug to treat a rare lung condition after it ...
One major biotech investor just walked away from Viking Therapeutics. Here’s what the move may—and may not—mean for the ...
Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback